Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Accounts Payables (2016 - 2025)

ENDRA Life Sciences has reported Accounts Payables over the past 6 years, most recently at $1.4 million for Q4 2021.

  • Quarterly Accounts Payables rose 55.07% to $1.4 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2021, up 55.07% year-over-year, with the annual reading at $1.4 million for FY2021, 55.07% up from the prior year.
  • Accounts Payables was $1.4 million for Q4 2021 at ENDRA Life Sciences, down from $1.4 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $1.7 million in Q4 2019 and troughed at $132646.0 in Q2 2017.
  • The 5-year median for Accounts Payables is $1.1 million (2018), against an average of $1.1 million.
  • Year-over-year, Accounts Payables surged 466.45% in 2018 and then plummeted 46.73% in 2020.
  • A 5-year view of Accounts Payables shows it stood at $848214.0 in 2017, then increased by 14.9% to $974583.0 in 2018, then surged by 75.31% to $1.7 million in 2019, then plummeted by 46.73% to $910183.0 in 2020, then skyrocketed by 55.07% to $1.4 million in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Accounts Payables are $1.4 million (Q4 2021), $1.4 million (Q3 2021), and $1.5 million (Q2 2021).